Compare AbCellera Biologics Inc (ABCL) vs International Business Machines Corp (IBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs International Business Machines Corp — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while International Business Machines Corp trades at $301.72 (market cap $287.73B). The key difference: International Business Machines Corp is far larger — about 122.4× AbCellera Biologics Inc's market cap, and International Business Machines Corp pays a 2.21% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | IBM | |
|---|---|---|
Market Cap | $2.35B | $287.73B |
Sector | Health | Technology |
52-Week High | $8.12 | $329.23 |
52-Week Low | $2.78 | $214.64 |
Enterprise Value | $1.99B | $345.75B |
Volume | — | 4,481,527 |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
IBM's stock trades at $306.13, up 5.74% today, and is near its consensus price target of $308.14. The technical outlook is bullish with strong moving average signals, though the 6-day RSI indicates overbought conditions. Fundamentally, the company reported revenue of $67.54B in 2025 with a net income margin of 15.61%, and it has beaten earnings estimates for the last three quarters. Recent news highlights product launches in AI and quantum computing.
The outlook is positive with continued earnings momentum and strategic focus on high-growth areas like AI and hybrid cloud. Key risks include competitive pressures in technology and execution challenges in innovation. Analyst sentiment is mixed but leans bullish, with 47% buy ratings. The stock offers a dividend yield supported by strong cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
